Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Hepatitis

  Free Subscription


Articles published in Arch Virol

Retrieve available abstracts of 17 articles:
HTML format



Single Articles


    May 2025
  1. SLEEM R, Salah A, Alziz AA, Daif AA, et al
    Inhibition of hepatitis C virus replication in HepG2 cells via modulation of the Raf-1 and interferon-alpha signaling pathways by thymoquinone.
    Arch Virol. 2025;170:120.
    PubMed     Abstract available


  2. DA SILVA H, Juniastuti, Amin M, Soares J, et al
    Genotypes, subtypes, and genetic variability of hepatitis B virus from blood donors in Timor-Leste.
    Arch Virol. 2025;170:119.
    PubMed     Abstract available


    March 2025
  3. SUPEKAR R, Sarkar J, Chakrabarti P, Biswas S, et al
    Diagnostic challenges due to hepatitis B virus surface antigen mutations outside the major hydrophilic region.
    Arch Virol. 2025;170:71.
    PubMed     Abstract available


    December 2024
  4. BIRLEM GE, Sita A, Gularte JS, de Souza da Silva D, et al
    Detection of a novel hepacivirus in wild cavies (Cavia aperea aperea).
    Arch Virol. 2024;170:19.
    PubMed     Abstract available


    November 2024
  5. TRIPATHY AS, Wagh P, Shahapure G, Walimbe AM, et al
    Association of IL1RN VNTR and NKG2A polymorphisms with hepatitis E infection, a case study from western India.
    Arch Virol. 2024;169:250.
    PubMed     Abstract available


  6. JIAO Q, Zhu S, Liao B, Liu H, et al
    An NLR family member X1 mutation (p.Arg707Cys) suppresses hepatitis B virus infection in hepatocytes and favors the interaction of retinoic acid-inducible gene 1 with mitochondrial antiviral signaling protein.
    Arch Virol. 2024;169:238.
    PubMed     Abstract available


  7. ALMAS I, Tariq S, Amin I, Shahid M, et al
    Molecular epidemiology and genetic characterization of hepatitis B virus in two major provinces of Pakistan.
    Arch Virol. 2024;169:239.
    PubMed     Abstract available


    October 2024
  8. KHAN S, Aggarwal S, Bhatia P, Yadav AK, et al
    Glucose and glutamine drive hepatitis E virus replication.
    Arch Virol. 2024;169:233.
    PubMed     Abstract available


    September 2024
  9. NJIFON AM, Modiyinji AF, Monamele CG, Mbouyap PR, et al
    A decade-long retrospective study of hepatitis C virus genetic diversity in Cameroon, 2013-2023: presence of a high proportion of unsubtypable and putative recombinant HCV strains.
    Arch Virol. 2024;169:197.
    PubMed     Abstract available


    June 2024
  10. SHALABY S, Awadin W, Karam R, Salem S, et al
    Pathological and phylogenetic characterization of a rare fowl adenovirus (FAdV-8b) associated with inclusion body hepatitis in naturally infected Meleagris gallopavo.
    Arch Virol. 2024;169:146.
    PubMed     Abstract available


    April 2024
  11. DAS S, Behera P, Shewale DJ, Bodele J, et al
    Development of an effective single-chain variable fragment recognizing a novel epitope in the hepatitis C virus E2 protein that restricts virus entry into hepatocytes.
    Arch Virol. 2024;169:112.
    PubMed     Abstract available


  12. SEDOHARA A, Takahashi K, Arai K, Arizono K, et al
    Characterization of mutations in hepatitis B virus DNA isolated from Japanese HBsAg-positive blood donors in 2021 and 2022.
    Arch Virol. 2024;169:103.
    PubMed     Abstract available


  13. WANG S, Xie Y, Liu F, Wang J, et al
    miR-3188 inhibits hepatitis B virus transcription by targeting Bcl-2.
    Arch Virol. 2024;169:88.
    PubMed     Abstract available


    February 2024
  14. SAID EM, Abdulaziz BA, Kassas ME, El Attar IH, et al
    Retraction Note: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir the
    Arch Virol. 2024;169:45.
    PubMed    


    January 2024
  15. MA X, Li Y, Zhu H, Lu K, et al
    ENPP1 inhibits the transcription activity of the hepatitis B virus pregenomic promoter by upregulating the acetylation of LMNB1.
    Arch Virol. 2024;169:36.
    PubMed     Abstract available


  16. GUPTA S, Parveen S
    Potential role of microRNAs in personalized medicine against hepatitis: a futuristic approach.
    Arch Virol. 2024;169:33.
    PubMed     Abstract available


    October 2023
  17. GAO H, Fan H, Xie H
    miR-HCC2 suppresses hepatitis B virus replication by inhibiting the activity of the enhancer I/X promoter.
    Arch Virol. 2023;168:282.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.